ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Approach to Managing a Postmenopausal Patient
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 190124" data-attributes="member: 13851"><p><strong>Figure 3. <span style="color: rgb(184, 49, 47)">Excess risks and benefits of menopausal hormone therapy expressed as the number of women per 1000 taking MHT for 5 years. </span><span style="color: rgb(44, 130, 201)">Data derived from the intervention phase of the Women’s Health Initiative Study of women ages 50–59 at study initiation 42. The data are extrapolated to five years.</span> <span style="color: rgb(26, 188, 156)">The results in the figure represent trends and are not statistically significant. The effects on overall mortality are likely beneficial but controversial 7,12,21. </span><span style="color: rgb(251, 160, 38)">Colorectal cancer incidence is reduced by E+SP but not by estrogen alone 7. Note that these risk estimates are based on data from studies of oral estrogen/synthetic progestogen combinations.</span><span style="color: rgb(147, 101, 184)"> Risks of transdermal estradiol, with or without progesterone, have not been studied in randomized controlled trials. Only observational data are available on risks of use of transdermal and oral MHT for durations longer than 5 years.</span> <span style="color: rgb(44, 130, 201)">From Manson AE et al 42 </span></strong></p><p>[ATTACH=full]11448[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 190124, member: 13851"] [B]Figure 3. [COLOR=rgb(184, 49, 47)]Excess risks and benefits of menopausal hormone therapy expressed as the number of women per 1000 taking MHT for 5 years. [/COLOR][COLOR=rgb(44, 130, 201)]Data derived from the intervention phase of the Women’s Health Initiative Study of women ages 50–59 at study initiation 42. The data are extrapolated to five years.[/COLOR] [COLOR=rgb(26, 188, 156)]The results in the figure represent trends and are not statistically significant. The effects on overall mortality are likely beneficial but controversial 7,12,21. [/COLOR][COLOR=rgb(251, 160, 38)]Colorectal cancer incidence is reduced by E+SP but not by estrogen alone 7. Note that these risk estimates are based on data from studies of oral estrogen/synthetic progestogen combinations.[/COLOR][COLOR=rgb(147, 101, 184)] Risks of transdermal estradiol, with or without progesterone, have not been studied in randomized controlled trials. Only observational data are available on risks of use of transdermal and oral MHT for durations longer than 5 years.[/COLOR] [COLOR=rgb(44, 130, 201)]From Manson AE et al 42 [/COLOR][/B] [ATTACH type="full" alt="Screenshot (2431).png"]11448[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Approach to Managing a Postmenopausal Patient
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top